Characteristics of lung cancers harboring NRAS mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research.
Times cited: 50
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Times cited: 239
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
- Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science translational medicine. 2011 Academic Article GET IT